Rikoon Group’s CRISPR Therapeutics CRSP Stock Holding History

Rikoon Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$464K	Buy	3,812 +365	+11%	+$55.1K	0.12%	143
2020 Q4	$528K	Sell	3,447 -640	-16%	-$75.6K	0.15%	135
2020 Q3	$342K	Sell	4,087 -290	-7%	-$25.7K	0.11%	155
2020 Q2	$322K	Sell	4,377 -656	-13%	-$38.4K	0.11%	150
2020 Q1	$213K	Buy	5,033 +120	+2%	+$6.2K	0.09%	170
2019 Q4	$299K	Sell	4,913 -1,175	-19%	-$64.2K	0.1%	166
2019 Q3	$250K	Sell	6,088 -266	-4%	-$12.7K	0.09%	174
2019 Q2	$299K	Hold	6,354	–	–	0.11%	160
2019 Q1	$227K	Buy	+6,354	New	+$220K	0.08%	189

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Rikoon Group's CRSP Position: Q1 2021 in Review

Rikoon Group increased its CRISPR Therapeutics (CRSP) stake by 11% in Q1 2021, buying an estimated $55.1K and bringing the position to 3,812 shares worth $464K. The position accounts for 0.12% of the portfolio, ranked #143.

Rikoon Group first reported a position in CRSP in Q1 2019 and has held it in 9 quarters since. The position peaked at $528K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

Rikoon Group held 3,812 shares of CRISPR Therapeutics worth $464K as of Q1 2021.
Rikoon Group bought 365 CRISPR Therapeutics shares in Q1 2021, an estimated $55.1K.
CRISPR Therapeutics made up 0.12% of Rikoon Group's portfolio in Q1 2021, its #143 holding.
Rikoon Group first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 9 quarters since.
Rikoon Group's CRISPR Therapeutics position peaked at $528K in Q4 2020.
443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Rikoon Group's 13F filing for Q1 2021, filed 14 May 2021.